ArticleBJU international2026
Characteristics and outcomes of men presenting with complications of metastatic prostate cancer.
Article in BJU international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
objectivesTo describe the incidence, characteristics and mortality of men who present with complications of metastatic prostate cancer, a previously under-reported population. We investigate men who present with and without malignant ureteric obstruction (MUO) and skeletal-related events (SREs), collectively termed 'metastatic-related events' (MREs). PATIENTS AND
methodsWe used the English Cancer Registry linked to hospital administrative data to identify men diagnosed with metastatic prostate cancer between January 2015 and December 2022. Poisson regression models estimated adjusted relative risks (aRRs) of presenting with MREs. The cumulative incidences of overall and prostate cancer-specific death were estimated for each MRE subgroup (metastatic without MRE, MUO, SRE, and MUO and SRE in combination).
resultsOf 48 171 men diagnosed with primary metastatic disease, 4272 (8.9%) presented with MREs. Of these men, 2453 (57.4%) had MUO, 1738 (40.7%) had a SRE, and 81 (1.9%) had both. Men aged ≥80 years had the highest risk (9.8% [1604/16452]) of presenting with MREs. Men aged 70-79 years (8.0% [1470/18397]) (aRR 0.82, 95% confidence interval [CI] 0.77-0.88) and men aged 60-69 years (8.9% [916/10297]) (aRR 0.91, 95%CI 0.84-0.98) had lower risks. Men from the most deprived neighbourhoods (9.3% [706/7609]) (aRR 1.27, 95% CI 1.15-1.40) had greater risks of presenting with MREs than those from the least deprived neighbourhoods (8.0% [868/10865]). The proportion of men presenting with MREs varied across geographical regions, ranging from 4.6% (288/6233) to 11.7% (461/3951). The 5-year overall mortality for men presenting without MREs was 57.8% (95% CI 57.2-58.4%), compared to 77.1% (95% CI 74.9-79.2%) with MUO, 66.8% (95% CI 64.1-69.4%) with a SRE and 84.4% (95% CI 74.1-94.7%) with both.
conclusionsThe risk of presenting with metastatic prostate cancer and MREs varies according to age, socioeconomic deprivation, and residential region. These men have poorer survival outcomes than men diagnosed without MREs at diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.